Analyst Reco. Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
4.22 ^USD	-6.64%		-8.86%	-43.43%

05-22	HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	MT
05-09	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	05-22	MT
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	03-21	MT
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target	12-13	MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target	12-08	MT
Morgan Stanley Adjusts Price Target on ACELYRIN to $13 From $19, Maintains Equal-Weight Rating	11-28	MT
Jefferies Adjusts ACELYRIN Price Target to $12 From $15, Maintains Buy Rating	11-28	MT
Morgan Stanley Downgrades ACELYRIN to Equalweight From Overweight, Cuts Price Target to $19 From $39	13/09/23	MT
Morgan Stanley Adjusts Price Target on Acelyrin to $39 From $29, Maintains Overweight Rating	05/09/23	MT
HC Wainwright Starts Acelyrin at Buy, $44 Price Target	05/09/23	MT
Morgan Stanley Initiates Coverage on Acelyrin With Overweight Rating, $29 Price Target	30/05/23	MT
Jefferies Starts Acelyrin at Buy With $31 Price Target	30/05/23	MT
Piper Sandler Initiates Acelyrin at Overweight With $68 Price Target	30/05/23	MT
TD Cowen Starts Acelyrin at Outperform	30/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer